$44.79
-2.46-5.21%
Last update: Nov 5, 4:00 PM
Enliven Therapeutics Inc
ELVNNASDAQ
The average analyst price target for Enliven Therapeutics is $66.67, 48.9% above the current price. Of 12 analysts, 12 rate it Buy. Targets range from $27 to $82. The latest change came on Oct 19, 2026, when HC Wainwright & Co. raised its price target on Enliven Therapeutics from $65 to $73 and kept a Buy rating.
Price Target Range — 10 Quarters
Analyst Consensus — 12 Analysts
Rating Trend — Last 9 Months
